{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ccedfa28-6976-4c9a-99e8-ed7ca7ad0e42 --><h2>Changes</h2><!-- end field ccedfa28-6976-4c9a-99e8-ed7ca7ad0e42 -->","summary":null,"htmlStringContent":"<!-- begin item 70054b48-c53c-42b3-9dbc-027a6b8e684e --><!-- begin field 959ef74e-8bd5-481a-b808-f37560cd41a1 --><p><strong>November 2020 to January 2021 </strong>— reviewed. A literature search was conducted in November 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring to improve clarity and navigation. The recommendations have been updated in line with current literature. Information on the hyperglycaemic emergency complication of hyperosmolar hyperglycaemic state (HHS) has been added.</p><!-- end field 959ef74e-8bd5-481a-b808-f37560cd41a1 --><!-- end item 70054b48-c53c-42b3-9dbc-027a6b8e684e -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e86449c1-89e6-58e0-8240-144fff80914c","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ad9880b3-874c-4721-84ff-a44313a230a2 --><h3>Previous changes</h3><!-- end field ad9880b3-874c-4721-84ff-a44313a230a2 -->","summary":null,"htmlStringContent":"<!-- begin item b5212b40-042b-449c-b1dd-4ece00964a31 --><!-- begin field 1ae12c6b-18c2-41db-ab4e-7407087a1d95 --><p><strong>April 2020 </strong>— minor update. Adverse effects of sodium-glucose cotransporter 2 (SGLT-i2) inhibitors have been updated to include bullous pemphigoid, in line with the manufacturers' Summary of Product Characteristics (SPC) update. </p><p><strong>September 2019</strong> — minor update. The section on antihypertensive treatment has been updated in line with the NICE clinical guideline <em>Hypertension in adults: diagnosis and management </em>[NICE 2019].</p><p><strong>July 2019</strong> — minor update. Angioedema has been recognised as a very rare skin and subcutaneous tissue disorder in people taking dapagliflozin for type 2 diabetes.</p><p><strong>May 2019</strong> — minor update. Prescribing information updated for liraglutide as the manufacturer advises that blood glucose self-monitoring is recommended to adjust the dose of sulfonylurea and insulin, especially when liraglutide is started and insulin is reduced, using a stepwise approach. Diabetic ketoacidosis has been reported in insulin-dependent patients after rapid discontinuation or dose reduction of insulin [ABPI, 2019].</p><p><strong>August 2017</strong> — minor update. Bullous pemphigoid added as an adverse effect of gliptins as per updates to the manufacturer's Summary of Product Characteristics (SPC). </p><p><strong>May 2017</strong> — minor update. Information added on sodium–glucose cotransporter 2 (SGLT-2) inhibitors to reflect changes to the NICE clinical guideline <em>Type 2 diabetes in adults: management.</em></p><p><strong>January 2017</strong> — minor update. Information added on organic cation transporters in the section on prescribing Metformin, as per the<strong> </strong>manufacturer's Summary of Product Characteristics (SPC) for glucophage. Information also added on potential drug interaction with St John's wort, as per an update to the manufacturer's SPC for diamicron.</p><p><strong>December 2016</strong> — minor update.</p><ul><li>Information added on use of pioglitazone in patients with active bladder cancer following FDA review [FDA, 2016].</li><li>The adverse effects section for pioglitazone has been updated with information that bone fractures have been reported in both men and women [ABPI, 2016].</li><li>Information from a systematic review has been added to the basis for recommendation in the section on managing cardiovascular risk [BMJ, 2016].</li><li>The adverse effects and interactions sections have been updated to reflect changes to the manufacturer's Summary of Product Characteristics (SPC) for vildagliptin [ABPI, 2016].</li></ul><p><strong>November 2016 </strong>— minor update.</p><ul><li>The National Institute for Health and Care Excellence (NICE) quality standards for diabetes in children and young people have been added to this topic [NICE, 2016].</li><li>Additional information regarding referral to the diabetic eye screening programme has been added to reflect the November 2016 update to the NICE clinical guideline. </li><li>A recommendation from a Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update <em>SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis</em> [MHRA, 2016] has been added to this topic.</li><li>The adverse effects section for sulfonylureas has been updated to include information about skin and subcutaneous tissue disorders and drug rash with eosinophilia and systemic symptoms (DRESS) with gliclazide [ABPI, 2016].</li></ul><p><strong>October 2016 </strong>— minor update. Increased lipase and increased amylase added as common adverse effects of liraglutide. </p><p><strong>April to July 2016 </strong>— reviewed. A literature search was conducted in April 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with recommendations in the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 2 diabetes in adults: management (2015)</em> and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management (2015)</em>.</p><p><strong>October 2015</strong> — minor updates:</p><ul><li>Immune-mediated necrotizing myopathy (IMNM) has been included as a very rare adverse effect of some statins based on updates to manufacturers' Summaries of Product Characteristics (SPCs).</li><li>The prescribing information section has been updated to reflect the US Food and Drug Administration (FDA) adverse event database, which now includes severe joint pain as an adverse effect of DPP-4 inhibitors.</li></ul><p><strong>September 2015 </strong>— minor updates. The prescribing information section has been updated to include:</p><ul><li>Pruritus, arthropathy, and bullous pemphigoid as adverse effects of sitagliptin, based on an update to the manufacturer's SPC.</li><li>Advice from the Medicines and Healthcare products Regulatory Agency (MHRA) and the drug manufacturers that combination use of drugs from two classes of the renin-angiotensin system (RAS) blocking agents (for example an angiotensin-converting enzyme [ACE] inhibitor plus an angiotensin-II receptor antagonist or aliskiren) is not recommended.</li><li>Other common adverse effects of ACE inhibitors and a drug interaction between ramipril tablets (Tritace®) and vildagliptin, based on updates to the SPC for Tritace®.</li></ul><p><strong>August 2015 </strong>— minor update. The prescribing information section on clarithromycin has been updated to reflect changes to the manufacturer's SPC.</p><p><strong>July 2015 </strong>— minor update. Based on an update to the manufacturer's SPC, constipation has been added as an adverse effect of saxagliptin.</p><p><strong>April 2015 </strong>— minor update. Update to the text to clarify the MHRA warning that aliskiren should not be prescribed with different classes of RAS blocking drugs.</p><p><strong>March 2015 </strong>— minor update. Update to the text to reflect the adverse effect of rapid weight loss resulting in cholelithiasis for exenatide, based on the manufacturer's SPC.</p><p><strong>February 2015 </strong>— minor update. Update to reflect the National Institute for Health and Care Excellence (NICE) guideline and address differences between this and the current Clinical Knowledge Summaries (CKS) type 2 diabetes topic.</p><p><strong>September 2014 </strong>— two minor updates:</p><ul><li>The recommendations in the Scenario on managing lipids have been updated in line with the revised NICE guideline <em>Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (2014)</em>.</li><li>The World Health Organization (WHO) recommendation to use HbA1c to confirm the diagnosis of diabetes type 2 has been included.</li></ul><p><strong>August 2014 </strong>— minor update to reflect additional caution of history of pancreatitis for saxagliptin and vildagliptin, based on the manufacturers' SPCs.</p><p><strong>July 2014 </strong>— two minor updates: </p><ul><li>The evidence section on lipid modification therapy has been deleted because it is currently being updated in line with the NICE guideline on lipid modification.</li><li>Advice from the MHRA to not prescribe medicines from different classes of RAS blocking agents in combination (for example an ACE inhibitor plus an AIIRA) has been incorporated into the topic.</li></ul><p><strong>March 2014 </strong>— minor update. Information on the pharmacological treatment of neuropathic pain has been removed and a link to the CKS topic on <em>Neuropathic pain - drug treatment</em> inserted.</p><p><strong>January 2014 </strong>— minor update. The prescribing information regarding antiplatelet drugs has been removed and a link to the CKS topic on <em>Antiplatelet treatment</em> inserted.</p><p><strong>December 2013 </strong>— two minor updates:</p><ul><li>Prescribing information has been updated in line with the SPC for perindopril.</li><li>Text has been removed from the section on antiplatelet treatment and links added to the updated CKS topic on <em>Antiplatelet treatment</em>.</li></ul><p><strong>September 2013</strong> — minor update to the text to reflect current European Medicines Agency (EMA) recommendations regarding metoclopramide.</p><p><strong>July 2013 </strong>— minor update. Links to the Driver and Vehicle Licensing Agency (DVLA) website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 Quality and Outcomes Framework (QOF) options for local implementation have been added to this topic.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2013 </strong>— minor update. Removed the black triangle status from sitagliptin as this is no longer a black triangle drug. Change to the text to reflect safety advice issued by the MHRA regarding gliptins. Update to the text to reflect safety advice issued by the MHRA for simvastatin.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (www.medicines.org.uk) have been updated.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>July 2012 </strong>— minor update. The section on goals and outcome measures has been updated to reflect changes to the NICE <em>Diabetes in adults</em> quality standards.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012 </strong>— minor update. Issued in April 2012. This topic has been updated to include: </p><ul><li>A section on management of a person with type 2 diabetes during periods of fasting (such as during Ramadan).</li><li>Information from guidelines commissioned by NHS Diabetes on 'Recognition, treatment and prevention of hypoglycaemia in the community'.</li><li>New information about doses, contraindications, and adverse effects of gliptins.</li></ul><p><strong>January 2012 </strong>— minor updates. Issued in February 2012. This topic has been updated to include:</p><ul><li>Information from the MHRA about the slight risk of hyperglycaemia and diabetes with statin use.</li><li>Update to the manufacturers' SPCs to clarify that although liraglutide is not licensed for use in combination with insulin, Levemir® (insulin detemir [recombinant human insulin analogue]) is licenced to be used as add-on therapy to liraglutide treatment.</li></ul><p><strong>October to December 2011 </strong>— updated. Issued in January 2012. This topic has been updated to include: </p><ul><li>The MHRA warning on the interaction between systemic fusidic acid and statins.</li><li>Information on saxagliptin (Onglyza®) and linagliptin (Trajenta®), two new dipeptidyl peptidase-4 inhibitors licensed for the treatment of adults with type 2 diabetes to improve glycaemic control.</li><li>Information on the NICE technology appraisal <em>Liraglutide for the treatment of type 2 diabetes mellitus</em>.</li><li>Information on fitness to drive from the DVLA's <em>At a glance guide to the current medical standards of fitness to drive</em>.</li><li>A tabulated version of the treatment recommendations for blood glucose control, to aid navigation.</li></ul><p><strong>August 2011 </strong>— minor update. There is a small increased risk of bladder cancer associated with pioglitazone use. This information is based on advice from the MHRA and the EMA. Issued in September 2011.</p><p><strong>July 2011 </strong>— minor update. Cough is included as a very rare but possible adverse effect of candesartan. This information is based on the updated SPC for Amias®. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011</strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made. The NICE quality standards on the management of diabetes have been added.</p><p><strong>November 2010 </strong>— minor update. CKS is aware that some primary care trusts are still recommending gabapentin over pregabalin due to the significant price differences between these two drugs. Based on feedback from CKS external reviewers, gabapentin is also offered by CKS as an alternative to pregabalin if there is a local decision to prefer gabapentin over pregabalin for painful diabetic neuropathy. Issued in November 2010.</p><p><strong>October 2010 </strong>— minor update. Information on fitness to drive from the DVLA's <em>At a glance guide to the current medical standards of fitness to drive </em>has been added. Issued in October 2010.</p><p><strong>September 2010 </strong>— minor update. The topic has been amended to reflect information in the MHRA guidance <em>Rosiglitazone (Avandia, Avandamet): Recommended withdrawal from clinical use updated</em>. Rosiglitazone is no longer available. The UK marketing authorisation has been suspended because the benefits are no longer considered to outweigh the increase in cardiovascular risk associated with its use. Issued in September 2010.</p><p><strong>September 2010 </strong>— minor update. The supporting evidence section on Antiplatelet drugs has been updated. Issued in September 2010.</p><p><strong>August 2010 </strong>— minor update. The MHRA has issued a reminder that the current cardiovascular restrictions on rosiglitazone must be followed whilst the EMA review on the safety of rosiglitazone is ongoing. Issued in August 2010.</p><p><strong>July 2010 </strong>— updated to include new recommendations on the management of painful diabetic neuropathy published in the NICE guideline <em>Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings</em>.</p><p><strong>June 2010 </strong>— minor update. Advice that vitamin B12 deficiency may sometimes be caused by long-term treatment with metformin has been added to the adverse effects section. Issued in June 2010.</p><p><strong>April 2010 </strong>— minor update. The recommendations from the NHS Diabetes Working Group on when to recommend self-monitoring of blood glucose has been included in the relevant sections. It supports the advice that self-monitoring of blood glucose should only be offered with appropriate education and clear objectives in specific circumstances. Advice from the Scottish Intercollegiate Guidelines Network (SIGN) that aspirin should not be offered for primary prevention of cardiovascular disease (CVD) in people with diabetes has also been added. Issued in April 2010.</p><p><strong>December 2009 </strong>— minor update. The recommendations on when to consider antiplatelet therapy for primary prevention of CVD have been updated. Issued in December 2009.</p><p><strong>July to October 2009 </strong>— updated to include evidence and recommendations from the NICE short guideline T<em>ype 2 diabetes: newer agents for blood glucose control in type 2 diabetes</em> and new information on reporting HbA1c levels. A reminder from the MHRA that aspirin is not licensed for primary prevention of CVD has also been added. Issued in October 2009.</p><p><strong>July 2009 </strong>— minor update to clarify the advice from the MHRA on the use of ACE inhibitors and AIIRAs in women who are breastfeeding. Issued in July 2009.</p><p><strong>May 2009 </strong>— minor update to include drug safety advice from the MHRA on the use of ACE inhibitors and AIIRAs in women who are breastfeeding. Issued in June 2009.</p><p><strong>April 2009 </strong>— updated to include the indicators related to diabetes mellitus in the QOF of the General Medical Services contract in the section on goals and outcome measures. Issued in May 2009.</p><p><strong>March 2009 </strong>— minor update. Losartan has been reclassified as a black triangle drug by the MHRA. However, this is due to harmonisation of the SPCs across the European Union, not because of any newly identified safety issues. Issued in April 2009.</p><p><strong>July to December 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This CKS topic replaces previous topics on <em>Diabetes — foot disease</em>, <em>Diabetes — glycaemic control</em>, <em>Diabetes — hypertension</em>, <em>Diabetes — renal disease</em>, and <em>Diabetes — retinopathy</em>. Significant changes include: </p><ul><li>The recommendation to prescribe aspirin to all people with diabetes over the age of 50 years.</li><li>The recommendation to start insulin (before triple therapy with oral antidiabetic drugs) in primary care, providing the expertise and support are available.</li><li>The rapid-acting insulin secretagogues (nateglinide and repaglinide) are recommended as an alternative to sulphonylureas for people with irregular mealtimes. Prescriptions are included.</li><li>Recommendations for management of hypertension have altered — all people with type 2 diabetes should now be started on an ACE inhibitor first-line (unless contraindicated).</li><li>The decision on when to prescribe a lipid-modifying drug is more clearly expressed.</li><li>Treatment targets for lipids have changed.</li><li>Ezetimibe is now recommended, in addition to simvastatin, as an alternative to a higher-intensity statin for people with CVD or microalbuminuria who have not reached lipid targets on a lower-intensity statin. Prescriptions are included.</li></ul><!-- end field 1ae12c6b-18c2-41db-ab4e-7407087a1d95 --><!-- end item b5212b40-042b-449c-b1dd-4ece00964a31 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}